KYTX Stock Overview
A clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Kyverna Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.45 |
| 52 Week High | US$35.06 |
| 52 Week Low | US$3.41 |
| Beta | 0 |
| 1 Month Change | -26.44% |
| 3 Month Change | -34.29% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -88.50% |
Recent News & Updates
Kyverna Therapeutics: CAR T-Cells Trying To Impact Inflammatory Disorders
Dec 12Here's Why We're Watching Kyverna Therapeutics' (NASDAQ:KYTX) Cash Burn Situation
Nov 17
Shareholder Returns
| KYTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -15.9% | -2.4% | -2.1% |
| 1Y | n/a | -8.7% | 21.3% |
Return vs Industry: Insufficient data to determine how KYTX performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how KYTX performed against the US Market.
Price Volatility
| KYTX volatility | |
|---|---|
| KYTX Average Weekly Movement | 13.8% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: KYTX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: KYTX's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 119 | Warner Biddle | kyvernatx.com |
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases.
Kyverna Therapeutics, Inc. Fundamentals Summary
| KYTX fundamental statistics | |
|---|---|
| Market cap | US$164.05m |
| Earnings (TTM) | -US$110.65m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.3x
P/E RatioIs KYTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KYTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$96.15m |
| Gross Profit | -US$96.15m |
| Other Expenses | US$14.50m |
| Earnings | -US$110.65m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.56 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did KYTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 00:19 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kyverna Therapeutics, Inc. is covered by 5 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mitchell Kapoor | H.C. Wainwright & Co. |
| Lut Ming Cheng | J.P. Morgan |
| Thomas Smith | Leerink Partners LLC |